October 30, 2019
Shares of Johnson & Johnson (NYSE: JNJ) opened more than 3% higher on Wednesday after the company reported that 15 new tests from the same bottle of Johnson’s Baby Powder previously tested by the U.S. Food and Drug Administration (FDA) found no asbestos in the product.
The pharmaceutical giant said an additional 48 new laboratory tests of J&J’s baby powder recalled earlier this month confirmed the product does not contain the carcinogen.
“Rigorous and third-party testing confirms there is no asbestos in Johnson’s Baby Powder. We stand by the safety of our product,” the company said.
The New Brunswick, New Jersey-based company is facing a mountain of lawsuits claiming its talc-based baby powder contained asbestos, causing mesothelioma and ovarian cancer.
In previous talc trials, a St. Louis jury ordered J&J to pay USD 4.69 Billion to 22 women who alleged the company’s talc-based baby powder caused them to develop ovarian cancer. J&J is appealing the judgement and has won several other court cases alleging liability and damages.
Other recent verdicts ordered J&J to pay USD 325 Million and USD 25 Million to plaintiffs in California and New York, respectively.
The company is also facing securities lawsuits claiming it failed to disclose the alleged asbestos contamination in its baby powder, leading to billions worth of financial losses for investors from drops in the price of Johnson & Johnson’s stock.
52 week low/high
Five Companies that Got Affected by the Coronavirus Outbreak
Since early January the world’s number one concern is the in China originated novel coronavirus, COVID-19.
Owens & Minor Beats Fourth Quarter Earnings Guidance
Today, Owens & Minor, Inc. (NYSE: OMI) announced its financial results for the fourth quarter and year ended December 31, 2019 and outperformed the earnings guidance. The Company declared a net loss of USD 39 million for the fourth quarter...
Tilray, Inc. Announces Fourth Quarter and Full Fiscal Year 2019 Financial Results
Tilray, Inc. (NASDAQ: TLRY), reported its fourth quarter and full fiscal year ended 31, 2019 financial results. Tilray stock declined more than 13% on Tuesday morning, after the published earnings underperformed investor’s estimates. The Company...